WO1997013505A3 - UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE - Google Patents
UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE Download PDFInfo
- Publication number
- WO1997013505A3 WO1997013505A3 PCT/FR1996/001568 FR9601568W WO9713505A3 WO 1997013505 A3 WO1997013505 A3 WO 1997013505A3 FR 9601568 W FR9601568 W FR 9601568W WO 9713505 A3 WO9713505 A3 WO 9713505A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rar
- apoptosis
- specific agonist
- agonist ligand
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ319646A NZ319646A (en) | 1995-10-09 | 1996-10-08 | Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis |
AU72209/96A AU705993B2 (en) | 1995-10-09 | 1996-10-08 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
US09/051,407 US6593359B1 (en) | 1995-10-09 | 1996-10-08 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis |
JP09514767A JP3135266B2 (ja) | 1995-10-09 | 1996-10-08 | アポプトシス速度向上のためのRAR−γ−特異的アゴニストリガンドの使用 |
EP96933502A EP0854710A2 (fr) | 1995-10-09 | 1996-10-08 | UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-$g(g) POUR AUGMENTER LE TAUX D'APOPTOSE |
KR1019980702620A KR19990064139A (ko) | 1995-10-09 | 1996-10-08 | 세포 소멸 속도를 증가시키는 감마-알에이알-특이성 작용 물질리간드의 용도 |
PL96326077A PL185826B1 (pl) | 1995-10-09 | 1996-10-08 | Zastosowanie specyficznego ligandu agonistycznegoZastosowanie specyficznego ligandu agonistycznegoRAR-y do zwiększenia stopnia apoptozyRAR-y do zwiększenia stopnia apoptozy |
BR9610967A BR9610967A (pt) | 1995-10-09 | 1996-10-08 | Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele |
NO981592A NO981592L (no) | 1995-10-09 | 1998-04-07 | Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9512179A FR2739557B1 (fr) | 1995-10-09 | 1995-10-09 | Utilisation d'un ligand agoniste specifique rar-gamma |
FR95/12179 | 1995-10-09 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/051,407 A-371-Of-International US6593359B1 (en) | 1995-10-09 | 1996-10-08 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis |
US09/431,920 Division US6686386B1 (en) | 1995-10-09 | 1999-11-02 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis |
US09/624,771 Division US6506796B1 (en) | 1995-10-09 | 2000-07-25 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis |
US09/801,664 Continuation US20010018456A1 (en) | 1995-10-09 | 2001-03-09 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
US10/183,518 Continuation-In-Part US20030092758A1 (en) | 1995-10-09 | 2002-06-28 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997013505A2 WO1997013505A2 (fr) | 1997-04-17 |
WO1997013505A3 true WO1997013505A3 (fr) | 1997-05-29 |
Family
ID=9483613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/001568 WO1997013505A2 (fr) | 1995-10-09 | 1996-10-08 | UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE |
Country Status (16)
Country | Link |
---|---|
US (4) | US6593359B1 (fr) |
EP (1) | EP0854710A2 (fr) |
JP (1) | JP3135266B2 (fr) |
KR (1) | KR19990064139A (fr) |
CN (1) | CN1121857C (fr) |
AU (1) | AU705993B2 (fr) |
BR (1) | BR9610967A (fr) |
CA (1) | CA2231561A1 (fr) |
FR (1) | FR2739557B1 (fr) |
HU (1) | HUP9900453A3 (fr) |
NO (1) | NO981592L (fr) |
NZ (1) | NZ319646A (fr) |
PL (1) | PL185826B1 (fr) |
RU (1) | RU2188037C2 (fr) |
TR (1) | TR199800645T1 (fr) |
WO (1) | WO1997013505A2 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030053991A1 (en) * | 2000-10-04 | 2003-03-20 | Kingsman Alan John | Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders |
US20070213290A1 (en) * | 1996-10-17 | 2007-09-13 | Kingsman Alan J | Neurite regeneration |
US20040266715A1 (en) * | 1999-03-31 | 2004-12-30 | Wong Liang Fong | Neurite regeneration |
GB9907461D0 (en) * | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
FR2757852B1 (fr) | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
KR100440836B1 (ko) * | 1997-11-12 | 2004-07-19 | 에프. 호프만-라 로슈 아게 | 레티노이드 길항제를 이용한 제2형 t-보조세포 중재 면역질환의 치료 |
US6083973A (en) * | 1998-03-09 | 2000-07-04 | Syntex (U.S.A.) Inc. | Methods for inhibiting mucin secretion using RAR α selective antagonists |
US6949528B1 (en) * | 1998-03-18 | 2005-09-27 | Goddard John G | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
JO2178B1 (en) * | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
US20060151574A1 (en) * | 2002-11-29 | 2006-07-13 | Gpc Biotech Ag | Formulations useful against hepatitis C virus infections |
US20050202055A1 (en) * | 2004-03-11 | 2005-09-15 | Koichi Shudo, Tokyo, Japan | Anti-wrinkle agent |
WO2005092283A1 (fr) * | 2004-03-26 | 2005-10-06 | Dsm Ip Assets B.V. | Composition comprenant un inhibiteur d'hdac combine a un retinoide |
US7713266B2 (en) | 2005-05-20 | 2010-05-11 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
US7850683B2 (en) * | 2005-05-20 | 2010-12-14 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
US9254162B2 (en) | 2006-12-21 | 2016-02-09 | Myoscience, Inc. | Dermal and transdermal cryogenic microprobe systems |
US8409185B2 (en) | 2007-02-16 | 2013-04-02 | Myoscience, Inc. | Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling |
WO2009065061A1 (fr) | 2007-11-14 | 2009-05-22 | Myoscience, Inc. | Gestion de la douleur à l'aide du remodelage cryogénique |
CA2748043A1 (fr) | 2008-12-22 | 2010-07-01 | Myoscience, Inc. | Systeme de cryochirurgie integre avec fluide frigorigene et source d'energie electrique |
JP5986570B2 (ja) | 2010-09-01 | 2016-09-06 | トーマス・ジェファーソン・ユニバーシティThomas Jefferson University | 筋修復および再生のための組成物および方法 |
EP3616701A1 (fr) * | 2011-06-24 | 2020-03-04 | GRI Bio, Inc. | Prévention et traitement de maladies inflammatoires |
CA2861116A1 (fr) | 2012-01-13 | 2013-07-18 | Myoscience, Inc. | Systeme de filtration de sonde cryogenique |
BR112014017175A8 (pt) | 2012-01-13 | 2017-07-04 | Myoscience Inc | proteção de pele para remodelagem criogênica subdérmica para tratamentos cosméticos e outros |
EP2802279B1 (fr) | 2012-01-13 | 2017-08-16 | Myoscience, Inc. | Aiguille cryogénique avec régulation de la zone de congélation |
US9017318B2 (en) | 2012-01-20 | 2015-04-28 | Myoscience, Inc. | Cryogenic probe system and method |
WO2014146126A1 (fr) | 2013-03-15 | 2014-09-18 | Myoscience, Inc. | Méthodes et dispositifs cryogéniques de dissection par extrémité émoussée |
US9295512B2 (en) | 2013-03-15 | 2016-03-29 | Myoscience, Inc. | Methods and devices for pain management |
WO2014146127A1 (fr) | 2013-03-15 | 2014-09-18 | Myoscience, Inc. | Procédés et systèmes pour le traitement de la spasticité |
US9610112B2 (en) | 2013-03-15 | 2017-04-04 | Myoscience, Inc. | Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis |
WO2015069792A1 (fr) | 2013-11-05 | 2015-05-14 | Myoscience, Inc. | Système de traitement cryochirurgical sécurisé |
DK3380086T3 (da) | 2015-11-25 | 2021-11-22 | Io Therapeutics Inc | Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer |
US11311327B2 (en) | 2016-05-13 | 2022-04-26 | Pacira Cryotech, Inc. | Methods and systems for locating and treating nerves with cold therapy |
AU2017278220C1 (en) | 2016-06-10 | 2022-10-13 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
EP3651764A4 (fr) * | 2017-07-13 | 2021-09-22 | IO Therapeutics, Inc. | Composés rétinoïdes et rexinoïdes immunomodulateurs en combinaison avec des modulateurs immunitaires pour l'immunothérapie du cancer |
CN111148514A (zh) | 2017-08-31 | 2020-05-12 | Io治疗公司 | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 |
US11134998B2 (en) | 2017-11-15 | 2021-10-05 | Pacira Cryotech, Inc. | Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods |
US11135236B2 (en) * | 2018-04-10 | 2021-10-05 | Northwestern University | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003682A1 (fr) * | 1995-07-17 | 1997-02-06 | Centre International De Recherches Dermatologiques C.I.R.D. Galderma | Procedes de traitement de cancers a l'aide de 6-[3-[1-adamantyl]-4-hydroxyphenyl] |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786391A (en) * | 1995-01-11 | 1998-07-28 | Cornell Research Foundation, Inc. | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position |
-
1995
- 1995-10-09 FR FR9512179A patent/FR2739557B1/fr not_active Expired - Fee Related
-
1996
- 1996-10-08 CN CN96198769A patent/CN1121857C/zh not_active Expired - Fee Related
- 1996-10-08 RU RU98108590/14A patent/RU2188037C2/ru not_active IP Right Cessation
- 1996-10-08 KR KR1019980702620A patent/KR19990064139A/ko not_active Application Discontinuation
- 1996-10-08 CA CA002231561A patent/CA2231561A1/fr not_active Abandoned
- 1996-10-08 EP EP96933502A patent/EP0854710A2/fr not_active Withdrawn
- 1996-10-08 NZ NZ319646A patent/NZ319646A/xx unknown
- 1996-10-08 US US09/051,407 patent/US6593359B1/en not_active Expired - Fee Related
- 1996-10-08 HU HU9900453A patent/HUP9900453A3/hu unknown
- 1996-10-08 BR BR9610967A patent/BR9610967A/pt not_active Application Discontinuation
- 1996-10-08 JP JP09514767A patent/JP3135266B2/ja not_active Expired - Fee Related
- 1996-10-08 AU AU72209/96A patent/AU705993B2/en not_active Ceased
- 1996-10-08 TR TR1998/00645T patent/TR199800645T1/xx unknown
- 1996-10-08 PL PL96326077A patent/PL185826B1/pl not_active IP Right Cessation
- 1996-10-08 WO PCT/FR1996/001568 patent/WO1997013505A2/fr not_active Application Discontinuation
-
1998
- 1998-04-07 NO NO981592A patent/NO981592L/no not_active Application Discontinuation
-
1999
- 1999-11-02 US US09/431,920 patent/US6686386B1/en not_active Expired - Fee Related
-
2000
- 2000-07-25 US US09/624,771 patent/US6506796B1/en not_active Expired - Fee Related
-
2001
- 2001-03-09 US US09/801,664 patent/US20010018456A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003682A1 (fr) * | 1995-07-17 | 1997-02-06 | Centre International De Recherches Dermatologiques C.I.R.D. Galderma | Procedes de traitement de cancers a l'aide de 6-[3-[1-adamantyl]-4-hydroxyphenyl] |
Non-Patent Citations (3)
Title |
---|
J. CORBEIL ET AL.: "antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.", J. CLIN. INVEST., vol. 93, no. 5, 1994, pages 1981 - 1986, XP000646558 * |
M.F. BOEHM ET AL.: "design and synthesis of potent retinoid-X receptor selective ligands that induce apoptosis in leukemia cells.", J. MED. CHEM., vol. 38, no. 16, 1995, pages 3146 - 3155, XP000615461 * |
Z-M. SHAO ET AL.: "P53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells.", ONCOGENE, vol. 11, no. 3, 1995, pages 493 - 504, XP000575582 * |
Also Published As
Publication number | Publication date |
---|---|
NZ319646A (en) | 2000-08-25 |
JP3135266B2 (ja) | 2001-02-13 |
HUP9900453A3 (en) | 1999-11-29 |
US6506796B1 (en) | 2003-01-14 |
CN1203528A (zh) | 1998-12-30 |
CN1121857C (zh) | 2003-09-24 |
AU7220996A (en) | 1997-04-30 |
US6593359B1 (en) | 2003-07-15 |
RU2188037C2 (ru) | 2002-08-27 |
FR2739557A1 (fr) | 1997-04-11 |
NO981592L (no) | 1998-06-09 |
PL185826B1 (pl) | 2003-08-29 |
WO1997013505A2 (fr) | 1997-04-17 |
BR9610967A (pt) | 1999-03-02 |
US20010018456A1 (en) | 2001-08-30 |
US6686386B1 (en) | 2004-02-03 |
JPH11501661A (ja) | 1999-02-09 |
KR19990064139A (ko) | 1999-07-26 |
CA2231561A1 (fr) | 1997-04-17 |
AU705993B2 (en) | 1999-06-03 |
HUP9900453A2 (hu) | 1999-05-28 |
EP0854710A2 (fr) | 1998-07-29 |
TR199800645T1 (xx) | 1998-06-22 |
PL326077A1 (en) | 1998-08-17 |
FR2739557B1 (fr) | 1997-11-14 |
NO981592D0 (no) | 1998-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997013505A3 (fr) | UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE | |
DE69535095D1 (de) | Vorrichtung zum austeilen von gebrauchsfertiger visköser lösung sowie deren verwendung zum austeilen | |
AU5756194A (en) | Cosmetic applicator useful for cleansing, moisturizing and protecting the skin from diaper rash | |
PL312481A1 (en) | Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such | |
ATE165983T1 (de) | Reduktion von hautirritationen und hautwiderstand während einer iontophoresebehandlung | |
TR199801501T1 (xx) | Yeni form�lasyon. | |
NZ330860A (en) | Method of inhibiting photoaging of skin | |
ATE98469T1 (de) | Kosmetische verwendung von einer waessrigen dispersion bestehend aus organopolysiloxanen und aus einem vernetzten kopolymer von ammonium acrylat/acrylamid. | |
CA2100394A1 (fr) | Filtre solaire cosmetique | |
IL114229A0 (en) | Compositions for applying active substances to or through the skin | |
DE69600048D1 (de) | Kosmetisches Haarwaschmittel und dessen Verwendung | |
FR2715845B1 (fr) | Composition cosmétique et/ou dermatologique contenant du vinaigre. | |
DE69600106D1 (de) | Hautdepigmentierungs- und/oder Alterungsschutzmittel und seine Verwendung | |
DE69206628T2 (de) | Feine dispersion von melaninpigmente, seine herstellung sowie seine verwendung in die kosmetik. | |
WO1997003188A3 (fr) | Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux | |
FR2687572B1 (fr) | Utilisation de certains flavonouides dans des compositions cosmetiques, et procede de protection de la peau, ses phaneres et des compositions cosmetiques. | |
AU3549697A (en) | Extracting particles produced by the treating of human or animal nails | |
AU6991296A (en) | Novel compositions based on a synergistic combination of one or more vrd ligands and retinoids | |
ZA978631B (en) | W/o emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin. | |
DE69712578T2 (de) | Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase | |
FR2733148B1 (fr) | Composition pour lutter contre les taches et/ou le vieillissement de la peau, ses utilisations | |
ATE251906T1 (de) | Verwendung von vitamine e acetat | |
AU7485996A (en) | Neuropeptide y-y5 receptor | |
FR2710839B1 (fr) | Composition cosmétique et méthode de traitement esthétique s'opposant au vieillissement de la peau. | |
FR2718640B1 (fr) | Composition cosmétique et/ou dermatologique notamment pour dépigmenter la peau, ses utilisations. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96198769.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN HU JP KR MK MX NO NZ PL RU TR US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA CN HU JP KR MK MX NO NZ PL RU TR US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996933502 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2231561 Country of ref document: CA Ref document number: 2231561 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998/00645 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800300 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/002761 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 514767 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980702620 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 319646 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09051407 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996933502 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980702620 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980702620 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996933502 Country of ref document: EP |